PMGC vs Oramed Pharmaceuticals
ELAB and ORMP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELAB and ORMP compare
Oramed Pharmaceuticals is the larger company, worth 13 times as much as PMGC ($172M against $12.8M).
Oramed Pharmaceuticals pays a dividend yielding 6.1%; PMGC does not pay one.
Oramed Pharmaceuticals scores higher on the StockData Score (12 against 4 for PMGC), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELAB | ORMP |
|---|---|---|
| Size and price | ||
| Market cap | $12.8M | $172M |
| Share price | $1.58 | $4.13 |
| Change, 1 year | −99.9% | 81.1% |
| Change, 5 years | – | −84.4% |
| Beta (5Y) | 1.69 | 1.44 |
| Employees | 32 | 13 |
| StockData Score | ||
| Total score | 4 | 12 (better) |
| Valuation score | 3 (better) | 2 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 1.0× |
| P/S | 5.0× | – |
| P/B | 0.8× | – |
| PEG | – | 0.04 |
| FCF yield | – | −3.0% |
| Fair value | $3.13 | – |
| Margin of safety | 49.5% | – |
| Growth | ||
| Revenue growth, 5Y average | – | −5.8% |
| EPS growth, 5Y average | – | 12.8% |
| Profitability | ||
| Gross margin | 31.1% | – |
| Net margin | −523% | – |
| Return on equity | −105% | 113% (better) |
| Return on invested capital | – | −8.4% |
| Financial health | ||
| Current ratio | 1.36 | 4.98 (better) |
| Altman Z-score | −0.47 | 1.96 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 6.1% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 6.1% (better) |
| Ownership | ||
| Held by institutions | 0.33% | 40.3% |
| Held by insiders | 55.2% | 23.9% |
| Insider net buying, 12 months | – | −$1.2M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 0.51% | 4.2% |
Go deeper
- ELAB stock overview
- ELAB income statement
- ELAB valuation and score
- ORMP stock overview
- ORMP income statement
- ORMP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.